The Whys of Disrupting the Specialty Pharmacy Marketplace | PBMI 2024
Kerri Tanner, Pharm.D., the chief pharmacy officer of PayerAlly, says payers are looking for ways to rein in the escalating costs of specialty pharmacy drugs beyond the traditional techniques used by pharmacy benefit managers.
First. here is the obvious one: the rising cost of specialty drugs and their growing share of the "drug spend," although that trend has been blunted a bit by the glucagon-like peptide 1 (GLP-1) drugs.
Second, says Kerri Tanner, Pharm.D.,is a desire for new ways of controlling those costs beyond the "one set of solutions" typically used by pharmacy benefit managers such as exclusive networks, rebates and formularies.
"Now you see these new entrants to the market that are trying to disrupt and provide additional value to payers that they might not to get with an exclusive specialty network through their PBM," says the chief pharmacy of PayerAlly, a specialty pharmacy consulting firm.
Tanner gave a presentation specialty pharmacy marketplace disruptioin at the the 2024 PBMI Annual National Conference on Thursday. The conference was held in Orlando.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
